Anavex Lf SC (AVXL) Stock Price, Quote & News

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-c...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 689 3939

Website: www.anavex.com

Address:

630 5th Avenue, 20th Floor, New York, United States

papatrick Dec. 28 at 3:53 AM

$AVXL That's the ChristMassling Majic!!!

0 · Reply

junkjar291 Dec. 28 at 3:30 AM

$AVXL All the articles from alz-jouranls are AAIC conference abstracts.

0 · Reply

Georgejj Dec. 28 at 2:50 AM

$AVXL A Patient-Centric, Digital Multimodal Post-Market Approval Continuous Monitoring of Drug Safety & Efficacy Platform for Blarcamesine Audrey Gabelle, Marwan N. Sabbagh, Timo Grimmer, Luca Villa, Elizabeth Gordon, Mathilde Borrot, Ayoub Gueddou, Nicolas Guizard, Olivier Courreges, Kun Jin, William R. Chezem, Juan Carlos Lopez-Talavera, Christopher U Missling First published: 26 December 2025 https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz70859_106459 Good luck and GOD bless,

0 · Reply

bigbiob00m Dec. 28 at 1:53 AM

$AVXL April 2025 Missling knew Blarcamesine had no chance of approval. On 10Q: “The marketing approval process for pharmaceutical products is a lengthy, complex and highly regulated process and we cannot predict the outcome of any interactions with the regulatory authorities or when we will receive marketing approval, if at all. A finding that our Phase 2b/3 ANAVEX2-73-AD-004 clinical trial is insufficient to support the current marketing authorization in Alzheimer’s disease could lead us to decide, after consultation with regulatory authorities, to voluntarily withdraw our MAA for blarcamesine.”

1 · Reply

Georgejj Dec. 28 at 1:30 AM

$AVXL Wealth Quote of the Day by Charlie Munger: “The big money is not in the buying and the selling, but in the waiting” — why Munger believed patience is where millions are made https://m.economictimes.com/news/international/us/wealth-quote-of-the-day-by-charlie-munger-the-big-money-is-not-in-the-buying-and-the-selling-but-in-the-waiting-why-munger-believed-patience-is-where-millions-are-made/articleshow/126189017.cms Good luck and GOD bless,

0 · Reply

keyeaster Dec. 27 at 10:12 PM

$AVXL https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz70859_106527

1 · Reply

keyeaster Dec. 27 at 10:08 PM

$AVXL https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz70859_101346

0 · Reply

Georgejj Dec. 27 at 7:03 PM

$AVXL Anavex Life Sciences has already completed a Phase 2A to evaluate effectiveness of 3-71 in schizophrenia that could involve 50 patients.

2 · Reply

Alex1710 Dec. 27 at 6:49 PM

$AVXL There's one thing I would like Anavex to do on a very short time horizon and IMO would not be too costly. To conduct a Phase 2A to evaluate effectiveness of 3-71 in schizophrenia that could involve 50 patients.

1 · Reply

papatrick Dec. 27 at 2:48 PM

$AVXL Incredible!!! What a paper!!! They worked to develop that cell phone digital app, that method for regulators/health insurance companies/anavex and that paper without being sure Blarcamesine will be approved by EMA?? and taking the risk to be ridiculous in front of the scientific community as world leaders in their domain? And Alz association would publish such useless and ridiculous paper??? imo approval is in the pocket! And this pre pub was edited after the initial rejection trend news. Take your own deduction/conclusion. Mine was to buy more!

3 · Reply

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Dec 18, 2025, 7:30 AM EST - 9 days ago

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

Dec 12, 2025, 4:05 PM EST - 15 days ago

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease

Nov 26, 2025, 7:30 AM EST - 4 weeks ago

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 25, 2025, 11:53 AM EST - 4 weeks ago

Anavex Life Sciences Corp. (AVXL) Q4 2025 Earnings Call Transcript

Nov 25, 2025, 7:30 AM EST - 4 weeks ago

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Nov 19, 2025, 7:30 AM EST - 5 weeks ago

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

Nov 18, 2025, 7:30 AM EST - 5 weeks ago

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

Nov 14, 2025, 7:30 AM EST - 6 weeks ago

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

Oct 29, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group

Oct 10, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care'

Oct 2, 2025, 1:40 PM EDT - 3 months ago

Anavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For Schizophrenia

Oct 2, 2025, 7:35 AM EDT - 3 months ago

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Oct 2, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Sep 30, 2025, 8:30 AM EDT - 3 months ago

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial

Sep 9, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial

Sep 2, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Aug 26, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

Aug 20, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease

Aug 12, 2025, 10:38 AM EDT - 4 months ago

Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call Transcript

Aug 12, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Aug 5, 2025, 7:30 AM EDT - 5 months ago

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

Jul 31, 2025, 7:30 AM EDT - 5 months ago

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

May 15, 2025, 8:49 PM EDT - 8 months ago

Does Anavex's Alzheimer's Drug Actually Confer Benefit?

May 15, 2025, 12:21 PM EDT - 8 months ago

The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)

May 14, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 13, 2025, 9:25 AM EDT - 8 months ago

Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 1, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Apr 30, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Apr 23, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Apr 21, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Apr 5, 2025, 11:30 AM EDT - 9 months ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Mar 31, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 24, 2025, 7:30 AM EST - 10 months ago

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Feb 14, 2025, 6:02 PM EST - 11 months ago

Anavex: Looking At Different Statistical Approaches Before EMA Opinion

Feb 12, 2025, 3:13 PM EST - 11 months ago

Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025

Feb 12, 2025, 9:59 AM EST - 11 months ago

Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript

Feb 12, 2025, 7:30 AM EST - 11 months ago

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Feb 5, 2025, 7:30 AM EST - 11 months ago

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Jan 27, 2025, 7:30 AM EST - 11 months ago

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Jan 15, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

Jan 13, 2025, 7:30 AM EST - 1 year ago

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients

Jan 12, 2025, 11:21 AM EST - 1 year ago

Playing The Odds Of Anavex Alzheimer's Drug Approval

Jan 6, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 27, 2024, 7:30 AM EST - 1 year ago

Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision

Dec 26, 2024, 10:31 AM EST - 1 year ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA PYPD

papatrick Dec. 28 at 3:53 AM

$AVXL That's the ChristMassling Majic!!!

0 · Reply

junkjar291 Dec. 28 at 3:30 AM

$AVXL All the articles from alz-jouranls are AAIC conference abstracts.

0 · Reply

Georgejj Dec. 28 at 2:50 AM

0 · Reply

bigbiob00m Dec. 28 at 1:53 AM

1 · Reply

Georgejj Dec. 28 at 1:30 AM

0 · Reply

keyeaster Dec. 27 at 10:12 PM

$AVXL https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz70859_106527

1 · Reply

keyeaster Dec. 27 at 10:08 PM

$AVXL https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz70859_101346

0 · Reply

Georgejj Dec. 27 at 7:03 PM

$AVXL Anavex Life Sciences has already completed a Phase 2A to evaluate effectiveness of 3-71 in schizophrenia that could involve 50 patients.

2 · Reply

Alex1710 Dec. 27 at 6:49 PM

1 · Reply

papatrick Dec. 27 at 2:48 PM

3 · Reply

Sand_Pebble Dec. 27 at 1:14 PM

$AVXL Great find georgejj. The title of the article is "A Patient-Centric, Digital Multimodal Post-Market Approval Continuous Monitoring of Drug Safety & Efficacy Platform for Blarcamesine." IMO, this is what Anavex wanted to take to FDA instead of a larger stateside phase 3 IMO. We still get another swing at it with the reconsideration application. Hopefully we give FDA this post EMA approval phase 4 and not another phase 3.

2 · Reply

RBTinx Dec. 27 at 11:03 AM

$AVXL How does this information matter right now? EMA cares a too hoot about it. All this is irrelevant currently. And with FDA they have no chances as none of the trials were done in the US. A big mistake in hindsight. I am losing hope slowly and steadly because of the way their application was refuted. We need a miracle now.

1 · Reply

NorvaK Dec. 27 at 5:18 AM

$AVXL this needs to be bookmarked.

1 · Reply

Georgejj Dec. 27 at 4:25 AM

$AVXL Brand NEW patent application WO2025264845 - USE OF ANAVEX3-71 FOR MEDICAL TREATMENTS https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025264845&_cid=P20-MJNSMF-22582-1 Good luck and GOD bless,

0 · Reply

Georgejj Dec. 27 at 4:12 AM

$AVXL NEWS regarding Anavex Life Sciences https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz70859_106459 Good luck and GOD bless,

0 · Reply

Zerocool510 Dec. 27 at 3:15 AM

$AVXL Fingers Crossed we state solid facts and emphasis on what the EMA was undecided on during first review. Split vote could be a positive vote this time.

0 · Reply

SmartOptionsAlert Dec. 26 at 11:38 PM

🔎 $AVXL Options Scan Update (17:38 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai

0 · Reply

Series4Guy Dec. 26 at 9:02 PM

$AVXL EMA Re-examination Process (according to Grok) Reevaluation request on December 18, 2025 (estimated start late December 2025). Independent assessment by new rapporteur and co-rapporteur (estimated: January) Consultation with a Scientific Advisory Group (SAG) late February to early March EMA appoints new rapporteurs - January Grounds for re-examination reviewed January 2026 If SAG convened: Experts meet (typically ~Day 50), February to mid-March New assessment report prepared February to April Possible sponsor oral explanation to CHMP March to April 2026 CHMP adopts final re-examination opinion late March to May - likely at CHMP meetings: February 23-26, March 23-26, or April-May ^submitted Dec 18 ^duration: Up to 60 days (extendable with clock stops). ^SAG involvement: Typically 3-4 months total. ^final CHMP opinion: Late March to May (likely March 23-26 or subsequent meetings).

2 · Reply

Trainguy1 Dec. 26 at 7:36 PM

$AVXL I wonder if all of the non-partisan pharmaceutical professionals who endorsed Anavex’s peer-reviewed journal article (link below) would have voted, if on the CHMP, to recommend Blarcamesine for approval If so, then why did the actual CHMP think differently? If not, then what’s missing? Can the missing content be included in the re-submission package according to the EMA’s rules? If the answer to that final question is NO, then Anavex is spinning its wheels, and needs to change their strategy ASAP. https://www.sciencedirect.com/science/article/pii/S2274580724006083

5 · Reply

MoneyGroupLLC Dec. 26 at 7:29 PM

Enter: $AVXL Calls Strike Price: $4 Expiry Date: JAN 16 2026 Buy in Price: $0.15 - $0.16 Sell Price: $0.22 Profit : +44% (Turn every $1 into $1.44) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

J903625 Dec. 26 at 6:03 PM

$AVXL Stock Price still taking beatings after rejection. Missling on vacation right now. Skanky also. SHit out of luck after hoping for a merry christmas and got a huge FU

0 · Reply

AntonioChigurh Dec. 26 at 5:59 PM

$AVXL Missling has 2 FAILED trial designs and still in charge. No accountability since BOD are his college drinking buddies. On a normal legit biotech he should’ve been fired since Rett failure January 2024.

0 · Reply

Market Cap	325.23M
Revenue (ttm)	0.00
Net Income (ttm)	-46.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,614,300
Avg Vol	2,817,314
Day's Range	N/A - N/A
Shares Out	89.35M
Stochastic %K	12%
Beta	1.15
Analysts	Sell
Price Target	$22.00